Plain-English translation of NCT07317011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new screening approach for hepatitis delta, a serious viral infection that only affects people who already have hepatitis B. The study wants to see if automatically testing all hepatitis B patients for hepatitis delta—rather than waiting for doctors to remember to order the test—helps identify more people with this disease earlier and gets them connected to care faster.
Hepatitis delta is the most dangerous form of viral hepatitis, but it's often missed because doctors don't always test for it. This medication is a new treatment option that's become available recently, but patients can only benefit if they're diagnosed first. By testing everyone with hepatitis B automatically, doctors hope to find more cases before the disease causes serious liver damage.
You likely qualify if…
You likely don't qualify if…
You will have a blood test to check for hepatitis delta virus as part of your routine care at the hospital, addiction services clinic, or prison health services. If you test positive for hepatitis delta, the study will help make sure you're referred to a liver specialist for follow-up care and possible treatment. The study aims to make screening routine rather than optional, so doctors don't miss cases of this serious disease.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Italy
Enrollment target
~244 participants
Started
October 2025
Primary completion
September 2026
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eleonora Sfreddo
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.